rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lisata Therapeutics, Inc.

LSTA · Nasdaq

Health CareBiotechnologyNot moving yet

LSTA stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 17 weeks. It is 62.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 17
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
29 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders29-4 on the quarter
New · exited3 · 6
Reported value$3.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026278,837$948K+7,022+2.6%
Yakira Capital Management, Inc.new · filed 13 Aug 2026138,561$471K+138,561
CSS LLCadded · filed 14 Aug 2026110,422$375K+48,524+78.4%
DELTEC ASSET MANAGEMENT LLCreduced · filed 21 Jul 202683,197$283K-6,803−7.6%
Rangeley Capital, LLCadded · filed 14 Aug 202681,000$275K+6,000+8.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202672,632$247K+1,745+2.5%
BlackRock, Inc.unchanged · filed 7 Aug 202654,857$187K00.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202648,964$166K+14,047+40.2%
GTS SECURITIES LLCreduced · filed 14 Aug 202630,200$103K-1,196−3.8%
STATE STREET CORPunchanged · filed 7 Aug 202625,348$86K00.0%
31 Mar 2023 – 30 Jun 2026
162432Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Cynthia Louise Flowers Company insiderDirector · last 9 Jan 20260 · 0
David J. Mazzo Company insiderPresident & CEO · last 9 Jan 20261 · 0
Gregory B. Brown Company insiderDirector · last 9 Jan 20260 · 0
Heidi Henson Company insiderDirector · last 9 Jan 20260 · 0
James Nisco Company insiderSVP, Fin/Treas, Chief Actg Off · last 9 Jan 20260 · 0
Kristen K. Buck Company insiderEVP, R&D and CMO · last 9 Jan 20260 · 0
Mohammad Azab Company insiderDirector · last 9 Jan 20260 · 0
Steven M. Klosk Company insiderDirector · last 9 Jan 20261 · 0
Tariq Imam Company insiderSVP, Bus Dev, General Counsel · last 9 Jan 20260 · 0
David W. Slack Company insiderPresident & CBO · last 9 Jan 20230 · 0
Erkki Ruoslahti Company insiderDirector · last 9 Jan 20230 · 0
Todd C. Girolamo Company insiderCLO, SVP of Corp Dev · last 14 Jan 20220 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2024 · to 31 Dec 2025-124%
Share count trendFY 2024 · to 12 Mar 20262.2%
Cash and equivalentsFY 2024 · to 31 Dec 2025$16.0M
Free cash flowFY 2024 · to 31 Dec 2025−$16.0M

Analyst forecasts

No analyst forecasts yet.